Skip to main content
PLOS One logoLink to PLOS One
. 2023 Dec 5;18(12):e0295688. doi: 10.1371/journal.pone.0295688

Correction: The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia

Rashidul Alam Mahumud, Khorshed Alam, Jeff Dunn, Jeff Gow
PMCID: PMC10697506  PMID: 38051735

There is an error in the affiliations for the first author. Specifically, #3 was included in error and should not have been indicated. The correct affiliations are as follows:

Rashidul Alam Mahumud1,2,3*, Khorshed Alam1,2, Jeff Dunn1,4,5, Jeff Gow1,2,61 Health Economics and Policy Research, Centre for Health, Informatics and Economic Research, University of Southern Queensland, Toowoomba, Queensland, Australia, 2 School of Commerce, University of Southern Queensland, Toowoomba, QLD Australia, 3 Health and Epidemiology Research, Department of Statistics, University of Rajshahi, Rajshahi, Bangladesh, 4 Cancer Research Centre, Cancer Council Queensland, Fortitude Valley, QLD, Australia, 5 Prostate Cancer Foundation of Australia, St Leonards NSW, Australia, 6 School of Accounting, Economics and Finance, University of KwaZulu-Natal, Durban, South Africa

Additionally, there was an error in the corresponding author’s listed email addresses. Correspondence regarding this article should only be sent to the following email address: rashed.mahumud@usq.edu.au.

Reference

  • 1.Mahumud RA, Alam K, Dunn J, Gow J (2019) The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia. PLoS ONE 14(10): e0223658. 10.1371/journal.pone.0223658 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from PLOS ONE are provided here courtesy of PLOS

RESOURCES